Marie-Christine Alessi Selected Research

vasodilator-stimulated phosphoprotein

12/2019	Platelet reactivity inhibition following ticagrelor loading dose in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
8/2013	Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).
1/2013	Prasugrel monitoring and bleeding in real world patients.
10/2009	Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.
4/2008	Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marie-Christine Alessi Research Topics

Disease

37	Acute Coronary Syndrome 01/2021 - 10/2006
20	Hemorrhage 01/2021 - 12/2008
18	Thrombosis (Thrombus) 01/2022 - 09/2003
15	Obesity 01/2019 - 06/2002
11	Inflammation (Inflammations) 10/2020 - 09/2002
9	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2014 - 10/2006
8	Insulin Resistance 10/2012 - 01/2002
5	Thrombophilia 01/2021 - 06/2010
5	Body Weight (Weight, Body) 02/2019 - 07/2003
5	Thrombasthenia (Glanzmann Thrombasthenia) 01/2018 - 10/2012
5	Type 2 Diabetes Mellitus (MODY) 01/2015 - 06/2007
4	Myocardial Infarction 01/2021 - 02/2007
4	Atherosclerosis 07/2017 - 09/2002
3	Venous Thrombosis (Deep-Vein Thrombosis) 01/2021 - 06/2010
3	Infections 05/2018 - 01/2016
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2016 - 10/2006
3	Necrosis 03/2013 - 01/2012
3	Abdominal Obesity 11/2006 - 06/2002
2	Stroke (Strokes) 01/2021 - 01/2016
2	Human Influenza (Influenza) 05/2018 - 01/2017
2	Type III Leukocyte Adhesion Deficiency 01/2018 - 12/2017
2	Thrombocytopenia (Thrombopenia) 01/2017 - 12/2016
2	Ischemic Stroke 04/2016 - 01/2016
2	Hypertension (High Blood Pressure) 04/2016 - 06/2008
2	Bernard-Soulier Syndrome (Giant Platelet Syndrome) 09/2014 - 10/2013
2	Coronary Artery Disease (Coronary Atherosclerosis) 10/2013 - 02/2010
2	Weight Gain 01/2012 - 09/2003
1	Septic Shock (Toxic Shock Syndrome) 01/2022
1	von Willebrand Diseases (von Willebrand's Disease) 11/2020
1	Lung Injury 11/2020
1	Splenomegaly 10/2020
1	Autoimmune Diseases (Autoimmune Disease) 10/2020
1	Fibrosis (Cirrhosis) 10/2020
1	Ischemia 12/2019

Drug/Important Bio-Agent (IBA)

24	Clopidogrel (Plavix)FDA Link 01/2020 - 10/2006
11	Prasugrel Hydrochloride FDA Link 10/2014 - 12/2012
11	Plasminogen Activator Inhibitor 1IBA 04/2011 - 01/2002
7	TicagrelorIBA 01/2021 - 12/2013
7	Proteins (Proteins, Gene)FDA Link 10/2020 - 09/2003
7	Adenosine Diphosphate (ADP)IBA 01/2020 - 02/2007
6	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 03/2014 - 02/2007
5	vasodilator-stimulated phosphoproteinIBA 12/2019 - 04/2008
5	Plasminogen Activators (Plasminogen Activator)IBA 09/2011 - 01/2003
4	AntibodiesIBA 05/2018 - 12/2002
4	Biological ProductsIBA 12/2016 - 06/2007
4	CytokinesIBA 01/2015 - 09/2002
4	Cytochrome P-450 CYP2C19IBA 04/2013 - 04/2008
4	Plasminogen InactivatorsIBA 09/2011 - 01/2002
4	Insulin (Novolin)FDA Link 06/2008 - 10/2006
3	omega-Chloroacetophenone (Mace)IBA 01/2021 - 04/2016
3	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 10/2019 - 10/2013
3	ABO Blood-Group SystemIBA 01/2019 - 08/2012
3	CalciumIBA 07/2017 - 10/2012
3	IntegrinsIBA 07/2017 - 10/2012
3	EnzymesIBA 10/2011 - 01/2009
3	GlucocorticoidsIBA 11/2006 - 06/2002
2	thienopyridineIBA 01/2021 - 08/2013
2	AntigensIBA 01/2021 - 01/2018
2	Biomarkers (Surrogate Marker)IBA 11/2020 - 01/2016
2	Pharmaceutical PreparationsIBA 11/2020 - 12/2016
2	CollagenIBA 10/2019 - 01/2010
2	Formyl Peptide Receptors (Formyl Peptide Receptor)IBA 05/2018 - 01/2016
2	Thrombin FDA Link 01/2018 - 10/2012
2	DiglyceridesIBA 07/2017 - 01/2017
2	Fibrinogen (Factor I)FDA Link 01/2017 - 10/2013
2	DNA (Deoxyribonucleic Acid)IBA 01/2017 - 01/2012
2	Matrix Metalloproteinases (MMPs)IBA 01/2016 - 04/2011
2	ChemokinesIBA 01/2015 - 01/2011
2	ThienopyridinesIBA 01/2015 - 08/2013
2	von Willebrand FactorIBA 09/2014 - 08/2012
2	Protein SIBA 08/2012 - 06/2010
2	ElementsIBA 01/2012 - 06/2010
2	LaminsIBA 10/2011 - 02/2010
2	Protein Isoforms (Isoforms)IBA 06/2010 - 08/2003
2	Metalloproteases (Metalloproteinases)IBA 01/2009 - 11/2007
2	Glucose (Dextrose)FDA LinkGeneric 06/2008 - 10/2006
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2007 - 01/2007
2	tiplaxtininIBA 12/2006 - 10/2006
1	Fibrinolysin FDA Link 01/2022
1	Member 2 Protein Solute Carrier Family 44IBA 01/2021
1	Hemostatics (Antihemorrhagics)IBA 01/2021
1	EpitopesIBA 01/2021
1	A-factor (Streptomyces)IBA 01/2021
1	N 30IBA 11/2020
1	Receptor for Advanced Glycation End ProductsIBA 11/2020
1	Vitamin B 12 (Cyanocobalamin)FDA LinkGeneric 10/2020
1	AutoantibodiesIBA 10/2020
1	AntidotesIBA 01/2020
1	Perilipin-1IBA 01/2020
1	CD40 Ligand (CD40L)IBA 10/2019
1	Thromboxane B2IBA 02/2019
1	ProstaglandinsIBA 02/2019
1	Vasoconstrictor AgentsIBA 02/2019
1	Thromboxane Receptors (Thromboxane Receptor)IBA 02/2019

Therapy/Procedure

17	Therapeutics 10/2019 - 06/2002
7	Percutaneous Coronary Intervention 01/2021 - 10/2009
6	Stents 12/2019 - 05/2009
4	Platelet Transfusion (Blood Platelet Transfusions) 01/2020 - 01/2017
2	Hematopoietic Stem Cell Transplantation 01/2018 - 12/2017
2	Aftercare (After-Treatment) 04/2010 - 04/2008